Peptipedia
BioregulatorPreclinicalAnimal Studies

Vesugen

Also known as Lys-Glu-Asp, KED

A tripeptide bioregulator targeting vascular tissue that promotes restoration of blood vessel tissues and normalization of vascular function.

Preclinical research; approved in Russia as supplement
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

10-20 mg daily

Frequency

Once or twice daily

Duration

10-30 day cycles

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 10-20 mg daily via Oral capsules or sublingual, Once or twice daily. Dose range: 10-20 mg daily. Duration: 10-30 day cycles.

Timing & Administration

Administer via Oral capsules or sublingual. Frequency: Once or twice daily.

Mechanism of Action

Stimulates proliferation-associated protein Ki-67 in vascular endothelial cells, counteracting age-related decline through direct gene regulatory effects on vascular cells.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical research; approved in Russia as supplement.

Side Effects & Safety

Important Warnings

  • Not FDA approved
Generally well-tolerated
limited safety data outside Russia

References

No references available.

Related Peptides

Browse all →
LivagenBioregulator

A tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Khavinson that modulates chromatin structure. Studies in elderly subjects (75-88 years) showed activation of ribosomal genes.

View profile
OvagenBioregulator

A tripeptide bioregulator targeting liver and gastrointestinal tissue, derived from liver tissue extracts. Modulates gene expression related to detoxification, antioxidant defense, and cellular repair.

View profile
CortagenBioregulator

A tetrapeptide bioregulator (Ala-Glu-Asp-Pro) derived from cerebral cortex extracts. Studied for neuroprotection, neural differentiation, and cognitive support.

View profile